Lemaitre Vascular Inc is a global provider of medical devices and human tissue cryopreservation services largely used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser degree, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio of devices consists of brand name products that are used in arteries and veins and are well known to vascular surgeons. Lemaitre Vascular Inc also processes and cryopreserves human vascular and cardiac tissue through its RestoreFlow allografts business.

Lemaitre Vascular Inc generates revenue from the sale of its products and services, including anastomotic clips, biologic vascular and dialysis grafts, biologic vascular and cardiac patches, carotid shunts, embolectomy and occlusion catheters, radiopaque marking tape, synthetic vascular and dialysis grafts, and valvulotomes. Through its RestoreFlow allografts business, the company also processes and cryopreserves human vascular and cardiac tissue. The company sells its products and services primarily through a direct sales force and to a lesser extent through distributors in countries where it does not maintain a direct sales presence. Revenue is recognized at the time the product is used in surgery in certain consignment cases, and otherwise at shipment. The company's net sales increased by 13% to $185.1 million for the nine months ended September 30, 2025, driven by higher average selling prices, higher unit volumes shipped to customers, and additional sales representatives.

The company operates through the following segments: biologic products and synthetic products.

• The biologic products segment includes vascular and cardiac patches as well as vascular and dialysis grafts derived from human tissue cryopreservation services. In Q3 2025, biologics represented 54% of the company's worldwide sales. The principal biologic offerings are used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease.

• The synthetic products segment includes anastomotic clips, carotid shunts, embolectomy and occlusion catheters, radiopaque marking tape, synthetic vascular and dialysis grafts, and valvulotomes. These products are used in arteries and veins and are well known to vascular surgeons. The synthetic products segment contributes to the company's diversified portfolio of devices used in open surgical and minimally invasive endovascular procedures.

Lemaitre Vascular Inc competes in the peripheral vascular device market, which it estimates exceeds $5 billion annually worldwide, with the company's addressable market estimated at approximately $1 billion. The company has experienced success in lower-rivalry niche segments such as the valvulotome market, where its differentiated devices have historically allowed it to increase average selling prices without significant unit share loss. In contrast, the company faces greater competition in markets such as the polyester vascular graft market from larger companies with greater resources and lower per unit costs. Lemaitre Vascular Inc's competitive advantages include its focused call point strategy, its expansion of a worldwide direct sales force, and its use of acquisitions to penetrate the peripheral vascular device market.

The company serves vascular surgeons who treat peripheral vascular disease through both open surgical methods and endovascular techniques. Additionally, Lemaitre Vascular Inc has begun to explore adjacent market customers such as cardiac surgeons and interventional cardiologists. The company's products and services are used primarily by hospitals and clinics throughout the world, with direct-to-hospital sales representing 95% of total net sales for both the three and nine months ended September 30, 2025.